Vertically integrated pharma group making APIs, complex formulations, biosimilars and CDMO services.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 20 |
| Reserves | 1.3k | 1.5k | 1.8k | 1.8k | 1.8k | 2.4k | 2.4k | 2.6k |
| Borrowings | 390 | 846 | 683 | 798 | 937 | 588 | 593 | 660 |
| Other Liabilities | 270 | 308 | 370 | 323 | 347 | 351 | 465 | 455 |
| Total Liabilities | 2.0k | 2.6k | 2.9k | 2.9k | 3.1k | 3.3k | 3.5k | 3.7k |
| AssetsFixed Assets | 650 | 1.1k | 1.3k | 1.4k | 1.4k | 1.4k | 1.8k | 2.0k |
| CWIP | 666 | 541 | 506 | 655 | 719 | 822 | 534 | 431 |
| Investments | 10 | 21 | 34 | 43 | 40 | 35 | 32 | 58 |
| Other Assets | 662 | 959 | 993 | 838 | 950 | 1.0k | 1.1k | 1.2k |
| Total Assets | 2.0k | 2.6k | 2.9k | 2.9k | 3.1k | 3.3k | 3.5k | 3.7k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 147 | 124 | 47 | 105 | 180 | 137 | 132 | 342 |
| Cash from Investing | -196 | -290 | -404 | -286 | -232 | -171 | -198 | -326 |
| Cash from Financing | 10 | 176 | 436 | 83 | 46 | 47 | 63 | 14 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -151 | -220 | -302 | -226 | -46 | -48 | -111 | -15 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
SHILPAMED · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.